162 related articles for article (PubMed ID: 34122429)
1. Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors.
Bronte G; Verlicchi A; De Matteis S; Rossi A; Affatato A; Sullo FG; Gianni C; Canale M; Burgio MA; Delmonte A; Milella M; Crinò L
Front Immunol; 2021; 12():672219. PubMed ID: 34122429
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
3. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
[TBL] [Abstract][Full Text] [Related]
5. Regulatory (FoxP3
Koh J; Hur JY; Lee KY; Kim MS; Heo JY; Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Sci Rep; 2020 Nov; 10(1):18994. PubMed ID: 33149213
[TBL] [Abstract][Full Text] [Related]
6. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
7. Potential Novel Ovarian Cancer Treatment Targeting Myeloid-Derived Suppressor Cells.
Abiko K; Hayashi T; Yamaguchi K; Mandai M; Konishi I
Cancer Invest; 2021 Apr; 39(4):310-314. PubMed ID: 33428503
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
Takeyama Y; Kato M; Tamada S; Azuma Y; Shimizu Y; Iguchi T; Yamasaki T; Gi M; Wanibuchi H; Nakatani T
Cancer Lett; 2020 Jun; 479():89-99. PubMed ID: 32200039
[TBL] [Abstract][Full Text] [Related]
9. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
10. Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade.
Peranzoni E; Ingangi V; Masetto E; Pinton L; Marigo I
Front Immunol; 2020; 11():1590. PubMed ID: 32793228
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma.
Zhao X; Yue D; Qian J; Zhang L; Song J; Zhang B; Zhang C; Sun L; Ma Y; Zhang H; Wang C
Front Immunol; 2022; 13():794217. PubMed ID: 35173719
[TBL] [Abstract][Full Text] [Related]
12. High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis.
Bronte G; Petracci E; De Matteis S; Canale M; Zampiva I; Priano I; Cravero P; Andrikou K; Burgio MA; Ulivi P; Delmonte A; Crinò L
Front Immunol; 2022; 13():866561. PubMed ID: 35493483
[TBL] [Abstract][Full Text] [Related]
13. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
14. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.
Tobin RP; Jordan KR; Robinson WA; Davis D; Borges VF; Gonzalez R; Lewis KD; McCarter MD
Int Immunopharmacol; 2018 Oct; 63():282-291. PubMed ID: 30121453
[TBL] [Abstract][Full Text] [Related]
15. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
16. MDSC subtypes and CD39 expression on CD8
Koh J; Kim Y; Lee KY; Hur JY; Kim MS; Kim B; Cho HJ; Lee YC; Bae YH; Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Eur J Immunol; 2020 Nov; 50(11):1810-1819. PubMed ID: 32510574
[TBL] [Abstract][Full Text] [Related]
17. Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.
Yuan S; Hu X; Zhao Y; Wang Z
Front Immunol; 2020; 11():563622. PubMed ID: 33240259
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
Tian Y; Zhai X; Yan W; Zhu H; Yu J
Cancer Med; 2021 Jan; 10(1):3-14. PubMed ID: 33230935
[TBL] [Abstract][Full Text] [Related]
19. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
20. Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells.
Owen DH; Benner B; Pilcher C; Good L; Savardekar H; Norman R; Ghattas C; Shah M; Konda B; Verschraegen CF; Wesolowski R; Behbehani GK; Carson WE; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e487-e497. PubMed ID: 33234490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
